[Summary] is becoming a leading company in the field of cellular immunotherapy i
Beijing Yimiao Shenzhou Pharmaceutical Co., Ltd. (Yimiao Biotech) is dedicated to applying innovative gene and cell drug technologies to the treatment of malignant tumors, and is a leader in China's gene and cell drug industry. To date, it has completed five rounds of financing, with investments from several well-known domestic and international institutions, including Peter Thiel, Legend Capital, Cowin Capital, Capital Science and Technology Development Group, Shougang Fund, China Resources Fund, and Sherpa Investment. The company boasts a research and development team composed of highly educated and high-quality personnel, and is one of the first teams in China to engage in gene and cell technology research. Founders Dr. He Ting, Dr. Lu Xin'an, and Dr. Qi Feifei all graduated from Tsinghua University and jointly lead the research and development of two technology platforms for gene drug vectors and immune cells, establishing a leading-edge technology system. Dr. He Ting, CEO of the company, has received numerous honors including Zhongguancun High-end Talent Project Outstanding Talent, Beijing Science and Technology New Star, Beijing Young Eagle Talent, and DeepTech Life Sciences Annual Innovation Figure. He has been repeatedly invited to deliver keynote presentations at major domestic and international academic and industrial conferences, including Cell Therapy Asia, Asia Pharma R&D Leaders Summit, CAR-TCR Summit Asia, China Precision Medicine and Tumor Immunotherapy International Summit, China International Immunology & Gene Therapy Forum, Cell Immunotherapy Industry Summit, and China Disease Biotherapy Conference. The company possesses a self-developed comprehensive gene and cell drug technology platform that can support the development of various mainstream cell drugs and viral vector drugs, achieving a leading position. This platform consists of a large-scale plasmid preparation system, lentiviral vector preparation system, and primary immune cell preparation system, covering all core technologies for gene and cell drug research and development, production, and commercialization. The company has developed 1.1-class innovative drug candidates, coded IM19 and IM21, based on chimeric antigen receptor T-cell (CAR-T) technology, for the treatment of relapsed or refractory acute lymphoblastic leukemia, relapsed or refractory non-Hodgkin lymphoma, and relapsed or refractory multiple myeloma. The company has successively received honors such as National High-tech Enterprise, Zhongguancun High-tech Enterprise, Zhongguancun Golden Seed Enterprise, Beijing "Major New Drug Creation Special Project", Beijing "Science and Technology New Star", Beijing Science and Technology Enterprise Innovation Fund, Beijing "Young Eagle Talent", Beijing "Golden Bridge Seed Fund", Zhongguancun Frontier Reserve Project, China's Top 50 Most Investment-Value Enterprises, and Tsinghua University x-lab Annual Innovation Star.
What does Beijing Yimiao Shenzhou Biomedical Co., Ltd. require? Who is Yimiao Shenzhou hiring? Yimiao Shenzhou recruitment: 医疗卫生/美容保健类占比最多占41.7%，其次是生物/制药/化工/环保类占29.1%. What education can get in at Yimiao Shenzhou? 本科占比最多占64.1%，其次是硕士占28.2%. High education required at Yimiao Shenzhou? 硕士占28.2%，博士占7.8%. Work experience required at Yimiao Shenzhou? 1-3年占比最多占28.2%，其次是不限占27.2%. Where are the job locations at Yimiao Shenzhou? 北京占比最多占97.1%，其次是广州占1.9%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
